Skip to main content

Regeneron Pharmaceuticals income statement

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

Regeneron Pharmaceuticals reported revenue of $14.3 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 1.0% from fiscal 2024. Net income was $4.50 billion and diluted earnings per share $41.48.

From Regeneron Pharmaceuticals's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Regeneron Pharmaceuticals income statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$238.5M$379.3M$459.1M$445.8M$1.38B$2.10B$2.82B$4.10B$4.86B$5.87B$5.15B$6.56B$8.50B$16.07B$12.17B$13.12B$14.20B$14.34B$16.90B
Revenue growth—+59.1%+21.0%−2.9%+209%+52.7%+34.0%+45.5%+18.4%+20.8%−12.4%+27.4%+29.6%+89.1%−24.3%+7.8%+8.3%+1.0%—
Net interest income——————−$37.37M−$14.24M−$7.20M−$25.12M—————————
Cost of revenue$923.0K$1.69M$2.09M$4.22M$83.93M$118.0M$129.0M$241.7M$194.6M$202.5M$237.5M$402.8M———————
Gross profit$237.5M$377.6M$457.0M$441.6M$1.29B$1.99B$2.69B$3.86B$4.67B$5.67B$4.91B$6.15B———————
Gross margin99.6%99.6%99.5%99.1%93.9%94.4%95.4%94.1%96.0%96.6%95.4%93.9%———————
Research and development$274.9M$398.8M$489.3M$529.5M$625.6M$859.9M$1.27B$1.62B$2.05B$2.08B$1.47B$2.45B$2.65B$2.86B$3.59B$4.44B$5.13B$5.85B$6.60B
Selling, general and administrative$48.88M$52.92M$65.20M$117.3M$210.8M$346.4M$519.3M$838.5M$1.18B$1.32B$1.13B$1.34B$1.35B$1.82B$2.12B$2.63B$2.95B$2.70B$2.76B
Operating expenses$323.8M$451.7M$554.5M$646.8M$836.8M——————————————
Operating income−$86.25M−$74.10M−$97.47M−$205.2M$457.7M$743.0M$823.9M$1.25B$1.33B$2.08B$2.53B$2.21B$3.58B$8.95B$4.74B$4.05B$3.99B$3.58B$4.86B
Operating margin−36.2%−19.5%−21.2%−46.0%33.2%35.3%29.2%30.5%27.4%35.4%49.3%33.7%42.1%55.7%38.9%30.9%28.1%24.9%28.8%
Interest expense$7.75M$2.34M$9.12M$21.28M$45.30M$46.44M$37.37M$14.24M$7.20M$25.10M$28.20M$30.20M$56.90M$57.30M$59.40M$73.00M$55.20M$43.80M$46.70M
Other income and expense$9.47M$2.15M−$7.00M−$17.73M−$43.29M−$46.67M−$62.68M−$26.82M−$900.0K−$1.10M$19.10M$219.3M$233.8M$379.0M$119.9M$152.2M$789.2M$1.65B$822.3M
Income before tax−$76.78M−$71.95M−$104.5M−$222.9M$414.4M$696.4M$761.2M$1.23B$1.33B$2.08B$2.55B$2.43B$3.81B$9.33B$4.86B$4.20B$4.78B$5.23B$5.69B
Income tax expense$2.35M−$4.12M$0.00−$1.13M−$335.8M$282.6M$423.1M$589.0M$434.3M$880.0M$109.1M$313.3M$297.2M$1.25B$520.4M$245.7M$367.3M$725.8M$869.4M
Effective tax rate−3.1%5.7%0.0%0.5%−81.0%40.6%55.6%48.1%32.7%42.3%4.3%12.9%7.8%13.4%10.7%5.9%7.7%13.9%15.3%
Net income−$79.13M−$67.83M−$104.5M−$221.8M$750.3M$413.7M$338.1M$636.1M$895.5M$1.20B$2.44B$2.12B$3.51B$8.08B$4.34B$3.95B$4.41B$4.50B$4.82B
Net margin−33.2%−17.9%−22.8%−49.7%54.4%19.7%12.0%15.5%18.4%20.4%47.5%32.3%41.3%50.2%35.6%30.1%31.1%31.4%28.5%
Net income to common shareholders——−$104.5M−$221.8M$779.4M——————————————
EPS · diluted——−$1.26−$2.45$6.75$3.72$2.98$5.52$7.70$10.34$21.29$18.46$30.52$71.97$38.22$34.77$38.34$41.48$45.13
Diluted weighted average shares——82.9M90.6M115M111M113M115M116M116M115M115M115M112M114M114M115M109M107M
Basic weighted average shares——82.9M90.6M94.7M97.9M101M103M105M106M108M109M108M106M107M107M108M105M103M
EBITDA−$74.96M−$59.90M−$77.78M−$174.1M$494.7M$784.3M$876.6M$1.33B$1.44B$2.23B$2.68B$2.42B$3.81B$9.23B$5.08B$4.47B$4.47B$4.12B$5.38B
EBITDA margin−31.4%−15.8%−16.9%−39.0%35.9%37.3%31.1%32.3%29.5%37.9%52.1%36.9%44.9%57.4%41.7%34.1%31.5%28.7%31.8%
Depreciation & amortization$11.29M$14.20M$19.69M$31.08M$36.94M$41.20M$52.69M$74.91M$104.7M$145.5M$148.2M$210.3M$235.9M$286.2M$341.4M$421.0M$482.9M$543.7M$512.9M
Stock-based compensation$32.52M$31.26M$39.90M$56.09M$94.16M$215.4M$321.8M$459.0M$559.9M$507.3M$427.4M$464.3M$432.0M$601.7M$725.0M$885.0M$982.8M$993.7M$1.01B

Quarterly

Regeneron Pharmaceuticals income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$3.43B$3.15B$3.55B$3.72B$3.79B$3.03B$3.68B$3.75B$3.88B$3.61B$4.29B$5.12B
Research and development$1.18B$1.25B$1.20B$1.27B$1.41B$1.33B$1.42B$1.48B$1.63B$1.54B$1.63B$1.79B
Selling, general and administrative$737.7M$689.0M$758.8M$714.4M$792.2M$633.0M$634.2M$657.8M$775.0M$647.7M$662.1M$677.8M
Operating income$972.9M$751.4M$1.07B$1.18B$990.2M$591.7M$1.08B$1.03B$879.9M$642.9M$1.29B$2.05B
Operating margin28.3%23.9%30.2%31.7%26.1%19.5%29.4%27.3%22.7%17.8%30.1%40.0%
Interest expense$18.30M$16.10M$14.80M$13.80M$10.50M$8.70M$3.60M$19.30M$12.20M$12.90M$11.00M$10.60M
Other income and expense$174.7M−$50.70M$558.5M$313.5M−$32.10M$313.3M$439.2M$736.5M$163.8M$188.3M$234.3M$235.9M
Income before tax$1.15B$700.7M$1.63B$1.49B$958.1M$905.0M$1.52B$1.76B$1.04B$831.2M$1.53B$2.28B
Income tax expense−$12.00M−$21.30M$195.8M$152.4M$40.40M$96.30M$127.1M$303.3M$199.1M$104.0M$230.9M$335.4M
Effective tax rate−1.0%−3.0%12.0%10.2%4.2%10.6%8.4%17.2%19.1%12.5%15.1%14.7%
Net income$1.16B$722.0M$1.43B$1.34B$917.7M$808.7M$1.39B$1.46B$844.6M$727.2M$1.30B$1.95B
Net margin33.8%23.0%40.4%36.0%24.2%26.7%37.9%38.9%21.7%20.2%30.2%38.1%
EPS · diluted$10.20$6.27$12.41$11.54$8.08$7.27$12.81$13.62$7.84$6.75$12.23$18.45
Diluted weighted average shares114M115M115M116M114M111M109M107M108M108M106M106M
Basic weighted average shares106M108M108M108M108M107M105M104M103M104M103M102M
EBITDA$1.09B$865.5M$1.19B$1.30B$1.12B$718.6M$1.21B$1.16B$1.02B$766.1M$1.42B$2.17B
EBITDA margin31.6%27.5%33.6%35.0%29.5%23.7%33.0%31.0%26.4%21.2%33.0%42.4%
Depreciation & amortization$113.0M$114.1M$120.7M$121.7M$126.4M$126.9M$135.1M$136.7M$145.0M$123.2M$123.7M$121.0M
Stock-based compensation$240.4M$230.1M$223.2M$225.1M$304.4M$255.7M$251.7M$237.0M$249.3M$257.4M$243.0M$255.8M
Dividends per share—————$0.88$0.88$0.88—$0.94$0.94$0.94

The main figures as JSON and plain text. See data and methodology.

REGN in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.